Back

The potential impact of bisphosphonates on major adverse cardiovascular events: a study of 1,097,406 patients

30 August 2024 (17:00 - 17:50)
Organised by: Logo
Congress Presentation Part of: Integrating insights: from biomarkers to therapeutics in the management of acute coronary syndromes Epidemiology, Prognosis, Outcome ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Khaled Atieh

Baylor University Medical Center, Dallas (United States of America)

7 More presentations in this session

Presentation thumbnail
Increased circulating levels of standardized inflammatory and endothelial dysfunction biomarkers in patients with myocardial infarction with nonobstructive coronary arteries.
Doctor M. Espinosa Pascual (Madrid, ES)
Abstract Slides Video
Presentation thumbnail
Markers of coagulation and early coronary stent thrombosis
Doctor L. Galli (Vienna, AT)
Abstract Slides Video
Presentation thumbnail
The sooner the better? What is the optimal timing for coronary angiography in high-risk non-ST-elevation acute coronary syndrome
Doctor C. Carvalho (Viana do Castelo, PT)
Abstract Slides Video
Presentation thumbnail
Cangrelor use in ticagrelor-loaded ST-elevation myocardial infarction patients with high residual platelet reactivity: a randomized controlled trial.
Doctor A. Lemaitre (Caen, FR)
Abstract Slides Video
Presentation thumbnail
Mortality effects of beta-blockers on myocardial infarction in patients without reduced ejection fraction or heart failure in the contemporary reperfusion era : a systematic review and meta-analysis
Doctor P. Lee (Bronx, US)
Abstract Slides Video

Access the full session

Session thumbnail
Integrating insights: from biomarkers to therapeutics in the management of acute coronary syndromes

The Event

Event poster

ESC Congress 2024

30 August 2024 17:00 CET
You may be interested in
thumbnail
Congress Session
Novel pharmacological approaches in acute coronary syndromes
thumbnail
Congress Session
Improving pharmacotherapy in primary prevention
thumbnail
Congress Session
The broad spectrum of cardiovascular risk

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources